Print this page

Research Collaborations

The following entities and institutions are collaborating with researchers at the Prechter Bipolar Research Fund.

University of Michigan collaborations:

College of Engineering

College of Pharmacy 

School of Nursing

School of Social Work

School of Kinesiology

Ford School of Public Policy

Department of Mathematics

Department of Psychiatry

Department of Psychology

Department of Cell and Developmental Biology

Units that have requested samples from the Heinz C. Prechter Bipolar Genetics Repository:

School of Public Health - Genome and Exome Sequencing for Bipolar Disorder

Department of Neurology - Control fibroblast samples for ALS research

Department of Human Genetics - Control fibroblast samples for ASD research


National and international collaborations:

The following institutions contribute samples to the Heinz C. Prechter Bipolar Genetics Repository:

Cornell University

Johns Hopkins University *

Penn State Hershey College of Medicine

Stanford School of Medicine

Weill Cornell Medical College

Institutions of Higher Education that requested samples from the Heinz C. Prechter Bipolar Genetics Repository:

Indiana University
Requested DNA samples from participants with bipolar disorder for a collaborative research study that involved youth at risk. These were parent samples of the children. Clinical data accompanied these samples.

University of Texas Health Science Center
Requested cell lines from individuals with bipolar disorder, depression, and healthy controls to look at calcium biomarkers related to bipolar disorder. Clinical data accompanied these samples.

Michigan State University
Requested saliva and plasma samples and associated clinical data for the purpose of examining whether the metabolites and/or inflammatory biomarkers correlate with depressive severity or suicidality.

University of Chicago
-Requested biomarker and clinical data for bipolar, MDD, and healthy control participants
-Requested clinical outcome data for patients with bipolar disorder

University of Illinois, Urbana Champaign
Requested cell lines and corresponding clinical data to examine lithium response


Institutions of Higher Education that are using our PRIORI app:

Butler Hospital, which is the major affiliated teaching hospital for psychiatry and behavioral health at The Warren Alpert Medical School of Brown University. Read the press release about the $2.9 million grant the research group received to support the study of suicide risk assessment.

We are engaged in several national and international research projects in bipolar disorder.

PGBD study: Pharmacogenomics of Mood Stabilizer Response in Bipolar Disorder  

The Pharmacogenomics of Bipolar Disorder study (PGBD) is a research study of patients with bipolar disorder and the role of genes in their response to medications. The study focuses on two of the most commonly used mood stabilizing medications, lithium and valproate (Depakote®). The goal is to identify the genes that influence whether a patient will have a good response to these medications. This study began in 2010 and recently the last patient was enrolled at the Michigan site. They will be monitored for two years to determine if they are responsive to lithium or valproate. 

Study locations

United States:

University of California *
Principal Investigator (PI): John Kelsoe, M.D. 

Indiana University
PI: John Nurnberger, M.D. 

University of Chicago
PI: Elliot Gershon, M.D. 

University of Pennsylvania *
PI: Wade Berrettini, M.D.  

University of Iowa *
PI: William Coryell, M.D. 

Johns Hopkins University
PI: Peter Zandi, Ph.D. 

Case Western University
PI: Joseph Calabrese, M.D.  

University of Michigan
PI: Melvin McInnis, M.D. 

Mayo Clinic *
PI: Mark Frye, M.D.  


University of Bergen, Bergen, Norway
PI: Ketil Odegaard, M.D.

Dalhousie University, Halifax, Canada
PI: Martin Alda, M.D.

EMBARC study: Establishing Moderators and Biosignatures of Antidepressant Response for Clinical Care  

If you or a loved one has suffered from depression, you may already be aware that not all treatments work the same for everyone. Some people are helped quickly, while for others it may take weeks before they feel a difference.

The purpose of this study is to assess clinical and biological moderators and mediators (biomarkers) of treatment outcome that may help guide future treatment selection for those diagnosed with Major Depressive Disorder (MDD). It is our intention to develop a predictive model that integrates the best current evidence to provide personalized treatment for Major Depressive Disorder, which can be further modified as new evidence emerges.

Study locations:

Massachusetts General Hospital *
P.I.: Maurizio Fava, M.D.  

Columbia University
P.I.: Patrick J. McGrath, M.D. 
P.I.: Myrna Weissman, Ph.D.
Collaborating Scientist:  Ramin Parsey, M.D.

University of Texas Southwestern Medical Center *
P.I.: Madhukar H. Trivedi, M.D.

University of Michigan
P.I.: Melvin McInnis, M.D. 


CHOICE study: Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder

Bipolar CHOICE was a 6-month, multi-site, prospective, randomized clinical trial of outpatients with bipolar disorder. This study compares the effectiveness of quetiapine versus lithium, each with adjunctive personalized treatments (APTs). This study began in 2010 and was completed in 2014.

Study locations:

University of Pennsylvania
P.I.: Karl Rickels, M.D. 

Case Western Reserve
P.I.: Keming Gao, M.D.

Massachusetts General Hospital*
P.I.: Thilo Deckersbach, Ph.D.

Stanford University
P.I.: Terence Ketter, M.D.

University of Texas
P.I.: Charles Bowden, M.D.

University of Pittsburgh
P.I.: Edward Friedman, M.D.  

University of Michigan
P.I.: Melvin G. McInnis, M.D.

Vanderbilt University
P.I.: William V. Bobo, M.D.

Weill Cornell Medical College
P.I.: Jim Kocsis, M.D.

University of Cincinnati
P.I.: Susan L. McElroy, M.D.

University of Alabama at Birmingham
P.I.: Rick Shelton, M.D.


National Network of Depression Centers (NNDC)

The NNDC’s mission is to develop and foster connections among members to use the power of our network, to advance scientific discovery, and to provide stigma free, evidence-based care to patients with depressive and bipolar illnesses. The NNDC envisions a global experience that is without stigma, where all patients with depressive and bipolar illnesses receive effective treatment, and access to improved quality of life.

The Prechter Fund collaborates with many NNDC member sites; these are denoted by an asterisk (*) throughout this page.


Collaborative Research Grants Submitted

iPSC-based platform development for major psychiatric disorder modeling and discovery
A multi-site collaboration between Janssen Pharmaceuticals, Johns Hopkins University, University of California San Diego, Salk Institute, Cellular Dynamics Inc., and Sanford Burnham Institute is under consideration for funding with the National Institutes of Health (NIH). The focus of this innovative industry-academia based collaboration is to accelerate the pace of discovery for cellular models in bipolar disorder and other psychiatric disorders.


Additional research collaborations in progress:

The Prechter team is in discussions with scientists from the Van Andel Institute, the Pine Rest Christian Mental Health Services clinics, and Blue Cross Networks to pursue collaborative projects focused on the identification of large numbers of individuals with bipolar disorder to be assessed and monitored using technology-based methods.  


If you or your team is interested in collaborating with us, please contact our research director and principal investigator, Melvin McInnis, M.D.